Showing results (341-350 of 520) with videos related to
Sort By:
Pageof 52
Nano Letters|November 29, 2023
Universal Conductance Fluctuations in a MnBi2Te4 Thin FilmMolly P Andersen, Evgeny Mikheev, Ilan T Rosen, et al.Nuclear Receptor Signaling|December 31, 2015
Identification of potential glucocorticoid receptor therapeutic targets in multiple myelomaAlexandra L Thomas, Cristian Coarfa, Jun Qian, et al.Molecular Cancer Therapeutics|August 8, 2006
Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell linesMujahid A Rizvi, Kulsoom Ghias, Katharine M Davies, et al.Current Hematologic Malignancy Reports|May 22, 2020
Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive ReviewCosimo Di Raimondo, Vishwas Parekh, Joo Y Song, et al.The Journal of Investigative Dermatology|April 29, 2006
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathwayChristiane Querfeld, Mujahid A Rizvi, Timothy M Kuzel, et al.Bioorganic & Medicinal Chemistry Letters|July 16, 1999
Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cellsJ C Medina, D Roche, B Shan, et al.Journal of Medicinal Chemistry|August 1, 1988
Design, synthesis, and properties of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic acidsT Rosen, D T Chu, I M Lico, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1988
Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresisA M Zimmer, S T Rosen, S M Spies, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker for gene therapy trialsS M Overholt, T J Liu, D L Taylor, et al.British Journal of Haematology|April 26, 2014
Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II studyAndrew M Evens, Mitchell R Smith, Izidore S Lossos, et al.Pageof 52